Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Emergent Biosolutions (EBS)

Emergent Biosolutions (EBS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 460,600
  • Shares Outstanding, K 52,520
  • Annual Sales, $ 742,900 K
  • Annual Income, $ 52,600 K
  • EBIT $ 165 M
  • EBITDA $ 271 M
  • 60-Month Beta 2.41
  • Price/Sales 0.63
  • Price/Cash Flow 2.45
  • Price/Book 0.90

Options Overview Details

View History
  • Implied Volatility 73.95% (-19.31%)
  • Historical Volatility 101.39%
  • IV Percentile 24%
  • IV Rank 5.09%
  • IV High 509.14% on 04/04/25
  • IV Low 50.62% on 01/16/26
  • Expected Move (DTE 15) 0.98 (11.15%)
  • Put/Call Vol Ratio 3.09
  • Today's Volume 647
  • Volume Avg (30-Day) 709
  • Put/Call OI Ratio 0.38
  • Today's Open Interest 14,168
  • Open Int (30-Day) 13,084
  • Expected Range 7.79 to 9.75

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.05
  • Growth Rate Est. (year over year) +1,997,900.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.81 +12.29%
on 03/02/26
11.68 -24.91%
on 02/05/26
-2.64 (-23.14%)
since 02/04/26
3-Month
7.81 +12.29%
on 03/02/26
14.06 -37.62%
on 01/07/26
-3.28 (-27.22%)
since 12/04/25
52-Week
4.02 +118.16%
on 04/09/25
14.06 -37.62%
on 01/07/26
+2.38 (+37.25%)
since 03/04/25

Most Recent Stories

More News
Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors

GAITHERSBURG, Md., March 03, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the appointment of John D. Fowler, Jr. to its board of directors effective March 1, 2026....

EBS : 8.67 (-1.14%)
Emergent Biosolutions: Q4 Earnings Snapshot

Emergent Biosolutions: Q4 Earnings Snapshot

EBS : 8.67 (-1.14%)
Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results

Fourth Quarter 2025 Total Revenues of $148.7 million; Full Year 2025 Total Revenues of $742.9 million Fourth Quarter 2025 Net Loss of $54.6 million and Net Loss Margin of 37% Full Year 2025 Net Income...

EBS : 8.67 (-1.14%)
Emergent BioSolutions Announces Approximately $140 Million in Contract Awards with the Government of Canada, Strengthening Canada’s Leadership in Health Preparedness

WINNIPEG, Manitoba, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced a series of new contracts and a contract modification with the Public Health Agency of Canada (PHAC)...

EBS : 8.67 (-1.14%)
Emergent BioSolutions Announces New $50 Million Stock Repurchase Program

GAITHERSBURG, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that its Board of Directors authorized the repurchase of up to $50 million of the company’s...

EBS : 8.67 (-1.14%)
Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray Multipacks

Approval will broaden the NARCAN ® Nasal Spray portfolio, and improve cost-effectiveness by increasing flexibility and distribution efficiency of this life-saving medication  GAITHERSBURG,...

EBS : 8.67 (-1.14%)
Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

GAITHERSBURG, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 26, 2026, at 5:00 pm eastern time to discuss the financial...

EBS : 8.67 (-1.14%)
Emergent BioSolutions Receives U.S. FDA Approval on Supplemental New Drug Application for NARCAN® Nasal Spray to be Packaged in a New Carrying Case, Making Life-Saving Naloxone More Accessible for Everyday Preparedness

Since the U.S. prescription launch of NARCAN® Nasal Spray in 2016, the medicine has been trusted as a safe, effective way to reverse opioid overdoses, and today, new solutions like the NARCAN® carrying...

EBS : 8.67 (-1.14%)
Emergent BioSolutions Announces $100 Million Paydown of Term Loan Principal, a Significant Step Achieved Toward its Multi-year Transformation

GAITHERSBURG, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions, Inc. (NYSE: EBS) announced it made a voluntary prepayment of $100 million under its outstanding term loan facility in...

EBS : 8.67 (-1.14%)
Emergent BioSolutions Receives Delivery Order up to $21.5 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War in 2026

GAITHERSBURG, Md., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions (NYSE: EBS) announced it has received a delivery order valued at up to $21.5 million from the U.S. Department of War to...

EBS : 8.67 (-1.14%)

Business Summary

Emergent BioSolutions, Inc. is a global specialty biopharmaceutical company offering specialized products to health care providers and governments to combat emerging public health threats. It also supplies vaccines to domestic and international non-government organizations and governments in/ outside...

See More

Key Turning Points

3rd Resistance Point 9.34
2nd Resistance Point 9.18
1st Resistance Point 8.98
Last Price 8.67
1st Support Level 8.62
2nd Support Level 8.46
3rd Support Level 8.26

See More

52-Week High 14.06
Fibonacci 61.8% 10.22
Fibonacci 50% 9.04
Last Price 8.67
Fibonacci 38.2% 7.86
52-Week Low 4.02

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar